Palonosetron for the treatment of chemotherapy-induced nausea and vomiting

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 17, 2014, Pages 2599-2608

  Navari, Rudolph M ^a,b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b South Bend Medical Services Corp   (United States)

Author keywords

5 hydroxytryptamine 3 receptor antagonists; Antiemetics; Chemotherapy induced nausea and vomiting; Serotonin

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GENERIC DRUG; GRANISETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE; QUINUCLIDINE DERIVATIVE;

BONE MARROW TRANSPLANTATION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; META ANALYSIS (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); CHEMICALLY INDUCED; NAUSEA; QUALITY OF LIFE; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; ISOQUINOLINES; NAUSEA; QUALITY OF LIFE; QUINUCLIDINES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 84910087386     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.972366     Document Type: Review

References (66)

1. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-8
2. Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15:497-503
3. Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 2013;73:249-62
4. Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 2010;6:1074-84
5. Navari RM. The current status of the use of palonosetron. Expert Opin Pharmacother 2013;14:1281-4
6. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009;69:1853-8
7. Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmcol 2014;722:180-6
8. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009;28:1-7
9. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011;9:188-95
10. Navari RM. Treatment of chemotherapy-induced nausea. Community Oncol 2012;9:20-6
11. Stern RM, Koch KL, Andrews PLR. editors. Nausea: mechanisms and management. Oxford University Press; New York: 2011
12. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21(5):232-43
13. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98
14. NCCN Clinical Practice Guidelines in Oncology version 2. 2014. Antiemesis; National Comprehensive Cancer Network (NCCN). [online] Available from: http://www.nccn.org/professionals/physician-gls/PDF/antiemesis.pdf [Accessed 08 July 2014]
15. Koga T, Fukuda H. Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema in the pattern generator in the emetic act in dogs. Neurosci Res 1992;14:366-79
16. Yates BJ, Grelot L, Kerman IA, et al. Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Physiol 1994;267:R974-83
17. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol 2003;1:89-103
18. Hesketh PJ. New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer 2004;12:550-4
19. Simpson K, Spencer CM, McClellan KJ. Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000;59:1297-315
20. Kimura E, Niimi E, Watanabe A, et al. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 1996;23:477-81
21. Taguchi T, Tsukamoto F, Watanabe T, et al. Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 1999;26:1163-70
22. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18:163-73
23. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother 2003;37:1276-86
24. World Health Organization. Dolasetron mesylate and serious cardiovascular reactions. WHO Drug Info 2006;20(3):185
25. U.S. Food and Drug Information. FDA Drug Safety Communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate) [online]. Available from: http://www.fda.gov/Drugs.DrugSafety/usm237081.htm [Accessed 27 December 2010]
26. Dolasetron [online]. Available from: www.drugs.com/fda/dolasetron [Accessed 27 July 2012]
27. Ondansetron [online]. Available from: www.drugs.com/fda/ondansetron [Accessed 27 July 2012]
28. Roila F, Warr D, Clark-Snow R, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005;13:104-8
29. Geling O, Eichler H. Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-94
30. Hickok JT, Roscoe JA, Morrow GR, et al. 5-HT3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 2005;6:765-72
31. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized, comparative phase III trial. Lancet Oncol 2009;10:115-24
32. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30
33. Tuca A. Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review. Cancer Manage Res 2010;2:1-12
34. Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011;19:1609-17
35. Grous JJ, Riegel E, Gabrail N, et al. Phase III study of sustained granisetron (APF530) compared to palonosetron for the prevention of chemotherapy induced nausea and vomiting. J Clin Oncol 2009;27(15 Suppl):abstract 9627
36. Egler RM, Lee CH, Smith W, et al. Pharmacologic characterization of RS 25259-197, a novel and selective 5HT3 receptor antagonist in vivo. Br J Pharmacol 1995;114:860-6
37. Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol 2004;15:330-7
38. Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010;626:193-9
39. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer 2003;98:2473-82
40. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase II trial comparing single dose of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7
41. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9
42. Aapro M, Fabi A, Nole F, et al. Double-blind, randomized, controlled-study of the efficacy and tolerability of palonosetron plus dexamethasone for one day with or without dexamethasone on days two and three in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010;21:1083-8
43. Celio L, Denaro A, Agustoni F, et al. Palonosetron plus one-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol 2012;10:65-71
44. Boccia R, Grunberg S, Franco-Gonzales E, et al. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase III trial. Support Care Cancer 2013;44:1453-60
45. Stoltz R, Cyong J, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-HT3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004;44:520-31
46. Botrel T, Clark O, Clark L, et al. Efficacy of palonosetron compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic treatment: systematic review and meta-analysis. Support Care Cancer 2011;19:823-32
47. Schwartzberg L, Barbour SY, Morrow GR, et al. Pooled analysis of phase III studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 2014;22:469-77
48. Popovic M, Warr DG, DeAngelis C, et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2014;22:1485-97
49. Yavas C, Dogan U, Yavas G, et al. Acute effect of palonosetron on electrocardiographic parameters in cancer patients; a prospective study. Support Care Cancer 2012;20:343-7
50. Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 2012;20:1507-14
51. Morrow GR, Schwartzberg L, Barbour SY, et al. Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysis. J Com Supp Oncol 2014;12:250-8
52. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 2007;15:1285-91
53. Mizukami N, Yamauchi M, Kazuhiko K. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 2014;47:542-50
54. Hocking CM, Kichenadese G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 2014;22:1143-51
55. Bymaster FP, Calligaro D, Falcone J, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96
56. Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine. Eur J Pharmacol 2001;430:341-9
57. del Castillo N, Zimmerman BM, Tyler B, et al. 759C/T variants of the serotonin (5HT2C) receptor gene and weight gain in children and adolescents in long-term risperidone treatment. Clin Pharmacol Biopharm 2013;2:110
58. Einhorn LH, Brames MJ, Dreicer R, et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multi-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007;15:1293-300
59. Harnada S, Hinotsu S, Kawai K, et al. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Support Care Cancer 2014;22:2161-6
60. Mirabile A, Celio L, Magni M, et al. Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. Future Oncol 2014. [Epub ahead of print]
61. Ripaldi M, Parasole R, DeSimone G, et al. Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety. Bone Marrow Transplant 2010;45:1663-4
62. Rzepecki P, Pielichowski W, Oborska S, et al. Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. Transplant Proc 2009;41:3247-9
63. Musso M, Scalone R, Crescimanno A, et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 2010;45:123-7
64. Morganroth J, Parisi S, Moresino C, et al. High dose palonosetron does not alter parameters including QTC interval in healthy subjects: results of a dose-response, double-blind, randomized, parallel E14 study of palonosetron versus moxifloxacin or placebo[abstract 1156]. Eur J Cancer Suppl 2007;5:158
65. Federal Drug Administration Bulletin. FDA approves palonosetron for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients. ASCO Post 2014;5
66. Serotonin receptor antagonists for chemotherapy-induced nausea and vomiting. Available from: www.goodrx.com. [Last accessed 15 September 2014]